These studies demonstrated that pharmacologic inhibition of GLS1 with CB-839, combined with electron transport chain (ETC) inhibitor metformin, reduced primary tumor growth and metastasis by inhibiting glycolytic and TCA cycle activity (93). Here, GLS is linked to neoplasm.